Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Three new studies confirm cancer outcomes related to insurance, race, income

October 6, 2010
By Ronald Piana
Article

Researchers find that patients lacking private health insurance or are poor or black fare worse than other cancer patients.

Researchers find that patients lacking private health insurance or are poor or black fare worse than other cancer patients.

Lack of private health insurance made a marked difference in survival outcomes of women with uterine cancer, researchers from the American Cancer Society and the University of California, Irvine found.
“Uninsured and Medicaid and Medicare patients with uterine cancer are more likely to die within four years than privately insured patients,” stated lead researcher Stacey A. Fedewa, an epidemiologist at the ACS.

A retrospective analysis on 178,891 patients in the National Cancer Database showed that privately insured women had an unadjusted 4-year survival rate of almost 89%, compared with uninsured, approximately 81%; those on Medicaid, almost 76%; younger women insured through Medicare, 79%; and older women on Medicare, 69%.

Researchers also found that black women with uterine cancer had the lowest overall four-year survival rate, 63%, compared to whites and Hispanics, both 82%.
Some of the difference was due to access to care. Yet even taking treatment, insurance and other factors into account, black women still had a 32% greater risk of dying than white women.

The researchers find that other health factors, such as obesity and diabetes and cultural beliefs and quality of care, affect survival too.

In a second study, researchers led by Dr. Chyke Doubeni, an assistant professor of family medicine and community health at the University of Massachusetts Medical School, found that late-stage diagnosis of colon cancer was more common for residents of poor communities than for folks living in richer neighborhoods. The finding could explain higher death rates from colon cancer in disadvantaged areas, the researchers said.

By analyzing 6,934 cases of colorectal cancer included in a national study, the researchers found people in the poorest areas had a 13 percent greater incidence of colorectal cancer and 15 percent higher incidence of advanced colorectal cancer, compared with people in better-off areas. This held true even after taking into account education and other factors.

In a third report, a team led by Heather J. Hoffman, an assistant professor of epidemiology and biostatistics at George Washington University School of Public Health and Health Services, found that race played a larger role than insurance in getting a timely breast cancer diagnosis.

In a study of almost 1,000 women examined for breast cancer, white women with private insurance waited an average of 15.9 days between testing and diagnosis, while privately insured black women waited 27.1 days and Hispanics 51.4 days, the researchers found.

For women on Medicare or Medicaid, the wait between testing and diagnosis was 11.9 days for whites, 39.4 days for blacks and 70.8 days for Hispanics.
Amongst those without insurance, the wait was 44.5 days for whites compared with 59.7 days for blacks and 66.5 days for Hispanics.

Insurance affects the ability to obtain cancer screening and treatment, he said. But other barriers to care also exist, he added, pointing to cultural differences, health literacy, education.

And, while rarely overt, racism may be built into the health care system because the system fails to take racial and cultural differences into account, Carrasquillo added.

 

Recent Videos
Thoracic surgeon, Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
Identifying the Treatment Landscape for Advanced Lung Cancers
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Highlighting the DREAM Program for Late-Stage Lung Cancer Treatment
Combination Immunotherapy Strategies in Melanoma: Insights From Key Trials
Combination Immunotherapy Strategies in Melanoma: Insights From Key Trials
Clinical Perspectives: Single-Agent Vs Combination Immunotherapy for Melanoma
Clinical Perspectives: Single-Agent Vs Combination Immunotherapy for Melanoma
Trial Insights from TROPiCS-02 and DESTINY-Breast06 in HR+/HER2– Breast Cancer
Trial Insights from TROPiCS-02 and DESTINY-Breast06 in HR+/HER2– Breast Cancer
Neurological Toxicity Recognition: ICANS Assessment and Management
Neurological Toxicity Recognition: ICANS Assessment and Management
Essential Patient and Caregiver Education for Tarlatamab Treatment Success
Essential Patient and Caregiver Education for Tarlatamab Treatment Success
Looking Ahead in R/R FL: Unmet Needs and What’s Next
Looking Ahead in R/R FL: Unmet Needs and What’s Next
Collaborating With Community Providers in Treating Patients With Complex R/R FL
Collaborating With Community Providers in Treating Patients With Complex R/R FL
Comparing ADCs in HR+/HER2– Breast Cancer Without Head-to-Head Trials
Comparing ADCs in HR+/HER2– Breast Cancer Without Head-to-Head Trials
Related Content
Advertisement

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
Article

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


"Given the superior efficacy of [chemoimmunotherapy], it holds promise as a first-line neoadjuvant therapy for MIBC, providing greater benefits to patients," according to the study authors.

Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC

Russ Conroy
May 24th 2025
Article

Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer

52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer

Harper Niver;Caroline Lippe;W. Bradford Carter
May 23rd 2025
Article

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

Tim Cortese
May 23rd 2025
Article

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.

Related Content
Advertisement

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
Article

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


"Given the superior efficacy of [chemoimmunotherapy], it holds promise as a first-line neoadjuvant therapy for MIBC, providing greater benefits to patients," according to the study authors.

Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC

Russ Conroy
May 24th 2025
Article

Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer

52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer

Harper Niver;Caroline Lippe;W. Bradford Carter
May 23rd 2025
Article

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

CHMP Recommends Mirdametinib for EU Approval in Adult/Pediatric NF1-PN

Tim Cortese
May 23rd 2025
Article

The EMA’s CHMP has adopted a positive opinion for mirdametinib in patients with inoperable plexiform neurofibromas of neurofibromatosis type 1.

Advertisement
Advertisement
Advertisement
Advertisement
x
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.